No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine

Clinical Pharmacology in Drug Development

Volumn 3, Issue 3, 2014, Pages 187-193

  Elshoff, Jan Peer ^a   Cawello, Willi ^a   Andreas, Jens Otto ^a   Braun, Marina ^a  

^a UCB PHARMA   (Belgium)

Author keywords

CYP2C19; Drug drug interactions; Omeprazole; Pharmacokinetics; Rotigotine transdermal system

Indexed keywords

CYTOCHROME P450 2C19; OMEPRAZOLE; ROTIGOTINE; CYP2C19 PROTEIN, HUMAN; CYTOCHROME P450 2C19 INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; PROTON PUMP INHIBITOR; TETRALIN DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; APPLICATION SITE REACTION; ARTICLE; BIOEQUIVALENCE; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ERYTHEMA; FATIGUE; GASTROENTERITIS; HEADACHE; HOT FLUSH; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; MONOTHERAPY; NAUSEA; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; PAPULE; PHARYNGITIS; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; STEADY STATE; VESICULAR RASH; VOMITING; ADOLESCENT; AREA UNDER THE CURVE; BIOTRANSFORMATION; CUTANEOUS DRUG ADMINISTRATION; DRUG INTERACTION; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHARMACOGENETIC VARIANT; PHARMACOGENETICS; PHENOTYPE; SOUTH AFRICA; TRANSDERMAL PATCH; YOUNG ADULT;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2C19; CYTOCHROME P-450 CYP2C19 INHIBITORS; DOPAMINE AGONISTS; DRUG INTERACTIONS; GENOTYPE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PHARMACOGENETICS; PHARMACOGENOMIC VARIANTS; PHENOTYPE; PROTON PUMP INHIBITORS; SOUTH AFRICA; TETRAHYDRONAPHTHALENES; THIOPHENES; TRANSDERMAL PATCH; YOUNG ADULT;

EID: 84899990862     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.78     Document Type: Article

References (28)

1. Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology. 2005; 65(2 Suppl 1):S3-S5.
2. Rascol O, Perez-Lloret S. Rotigotine transdermal delivery for the treatment of Parkinson's disease. Expert Opin Pharmacother. 2009; 10:677-691.
3. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord. 2007; 22:2398-2404.
4. Watts RL, Wendt J, Nausieda PA, Boroojerdi B, Poole KH, Sommerville KW. Efficacy, safety, and tolerability of the rotigotine transdermal patch in patients with early-stage, idiopathic Parkinson's disease. A multicenter, multinational, randomized, double-blind, placebo-controlled trial. Mov Disord. 2004; 19(S9):S258.
5. LeWitt PA, Lyons KE, Pahwa R, SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology. 2007; 68:1262-1267.
6. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007; 6:513-520.
7. Trenkwalder C, Benes H, Poewe W, et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2008; 7:595-604.
8. Oertel WH, Benes H, Garcia-Borreguero D, et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med. 2010; 11:848-856.
9. Hening WA, Allen RP, Ondo WG, et al. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord. 2010; 25:1675-1683.
10. Swart PJ, Bronner GM, Bruins AP, Ensing K, Tepper PG, De Zeeuw RA. HPLC-UV atmospheric pressure ionization mass spectrometric determination of the dopamine D2 agonist N-0923 and its major metabolites after oxidative metabolism by rat-, monkey-, and human liver microsomes. Toxicol Methods. 1993; 3:279-290.
11. Swart PJ, Oelen WE, Bruins AP, Tepper PG, de Zeeuw RA. Determination of the dopamine D2 agonist N-0923 and its major metabolites in perfused rat livers by HPLC-UV-atmospheric pressure ionization mass spectrometry. J Anal Toxicol. 1994; 18:71-77.
12. Cawello W, Braun M, Boekens H. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metab Dispos. 2009; 37:2055-2060.
13. 14C]rotigotine by a patch formulation: a mass balance trial. Clin Pharmacokinet. 2007; 46:851-857.
14. UCB; Data on fi≤ Report DHGY1012, 2001.
15. Rodrigues AD, Rushmore TH. Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. Curr Drug Metab. 2002; 3:289-309.
16. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos. 2003; 31:815-832.
17. Pelkonen O, Mäenpää J, Taavitsainen P, Rautio A, Raunio H. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998; 28:1203-1253.
18. US Department of Health and Human Services. Food and Drug Administration. Guidance for Industry. Drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations, 2012. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf (Accessed May 2012).
19. European Medicines Agency. Note for guidance on the investigation of drug interactions, CHMP/EWP/560/95, 1997. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002966.pdf (Accessed May 2012).
20. Neupro® (Rotigotine Transdermal System). European Summary of Product Characteristics (last updated Sep 2012). UCB Manufacturing Ireland Ltd, Co. Clare, Ireland (Neupro -EMEA/H/C/000626-WS/0226/G). Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000626/human_med_000926.jsp&mid=WC0b01ac058001d124 (Accessed October 2012).
21. Suri A, Bramer SL. Effect of omeprazole on the metabolism of cilostazol. Clin Pharmacokinet. 1999; 37(Suppl 2):53-59.
22. Braun M, Elshoff JP, Andreas JO, Müller LI, Horstmann R. Influence of transdermal rotigotine on ovulation suppression by a combined oral contraceptive. Br J Clin Pharmacol. 2009; 68:386-394.
23. Braun M, Cawello W, Andreas JO, Boekens H, Horstmann R. Lack of pharmacokinetic interactions between transdermal rotigotine and oral levodopa/carbidopa. J Clin Pharmacol. 2009; 49:1047-1055.
24. Braun M, Cawello W, Boekens H, Horstmann R. Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine. Br J Clin Pharmacol. 2009; 67:209-215.
25. European Medicines Agency. Guideline on the investigation of bioequivalence, CPMP/EWP/QWP/1401/98, 2008. Available at: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003011.pdf (Accessed May 2012).
26. U.S. Department of Health and Human Services. Food and Drug Administration. Guidance for Industry. Skin irritation and sensitization testing of generic transdermal drug products, 1999. Available at: http://www.fda.gov/ohrms/dockets/98fr/990236Gd.pdf (Accessed May 2012).
27. Howden CW. Clinical pharmacology of omeprazole. Clin Pharmacokinet. 1991; 20:38-49.
28. Elshoff JP, Braun M, Andreas JO, Middle M, Cawello W. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, Phase I multiple dose studies. Clin Ther. 2012; 34:966-978.